Originator:Nektar Therapeutics, which licensed it in 2009.
Originator:Amylin, which was acquired by Bristol-Myers Squibb in 2012. BMS later partnered diabetes assets with AstraZeneca. Last year, AstraZeneca bought out BMS to fully own Amylin. Cost:~$1,500 per vial (>$150,000 per year for men and >$300,000 per year for women)
Movantik
Myalept
Originator:Organon BioSciences, which was acquired by Schering-Plough, which later was acquired by Merck. Cost:~$12,500 per month
Originator:Licensed from Dainippon Sumitomo Pharma in 2006.
Keytruda
Northera
Originator:Genzyme, which was acquired by Sanofi in 2011.
Cerdelga
Originator:In-house. Cost:~$380,000 per year
Originator:Fujisawa Pharmaceutical discovered ceftolozane and licensed it to Calixa Therapeutics, which was acquired by Cubist in 2009.
Vimizim
Originator:In-house. Cost:~$62,035 per year
Zerbaxa
Plegridy
Originator:BMS, which licensed it to Vanda in 2004.
Hetlioz
Originator:In-house. Read More:Volume 92 Issue 35 | pp. 52-55 September 1, 2014 As FDA Decision Loomed For Suvorexant, Chemists Discussed Sleep Drug Field’s Big Questions
Belsomra
Originator:BMS.
Farxiga
Originator:Paritaprevir was licensed in 2006 from Enanta Pharmaceuticals, ombitasvir was discovered in-house, andritonavir is an antiviral marketed for HIV by AbbVie. Cost:~$83,320 for 12 weeks
Viekira Pak
Originator:Discovered by Eli Lilly & Co., sold to InterMune, then to Targanta Therapeutics and acquired by the Medicines Co. in 2009. Read More:Volume 86 Issue 15 | pp. 15-20 April 14, 2008 An Uphill Battle
Orbactiv
Originator:In-house.
Originator:Kaken Pharmaceutical, which licensed it to Dow Pharmaceutical Sciences. Dow was acquired by Valeant in 2008.
Jublia
Jardiance
Originator:Marion Merrell Dow, which sold it to Vicuron Pharmaceuticals. Vicuron was later bought by Pfizer, which sold it to Durata, which was later acquired by Actavis. Read More:Volume 92 Issue 24 | pp. 9-14 June 16, 2014 A Bacterial Battle
Dalvance
Striverdi Respimat
Originator:KuDOS Pharmaceuticals, which AstraZeneca acquired in 2005. Read More:Volume 91 Issue 24 | pp. 13-18 June 17, 2013 Pushing Cancer Over The Edge
Lynparza
Originator:Calistoga Pharmaceuticals, which Gilead acquired in 2011. Cost:~$7,200 per month Read More:Volume 89 Issue 15 | pp. 15-19 April 11, 2011 PI3K At The Clinical Crossroads
Zydelig
Click
Originator:Licensed from MerLion Pharmaceuticals for otic use in 2011.
Originator:Millennium Pharmaceuticals, which was acquired by Takeda in 2008.
Entyvio
"FRUITFUL YEAR FDA approved 41 new drugs in 2014, an 18-year high and up from 27 in 2013." "FRUITFUL YEAR FDA approved 41 new drugs in 2014, an 18-year high and up from 27 in 2013." DRUG NAME ACTIVE INGREDIENT MARKETER DRUG TYPE (FOR KEY) MODE OF ACTION INDICATION DRUG NAME Originator Orphan drug? FDA breakthrough status Novel mode of action Cost (list price) Links Opdivo Nivolumab Bristol-Myers Squibb antibody PD-1 inhibitor Melanoma Opdivo Ono Pharmaceutical and Medarex. Medarex was acquired by Bristol-Myers Squibb in 2009 Yes "~$12,500 per month" Rapivab Peramivir BioCryst Pharmaceuticals small molecule Neuraminidase inhibitor Influenza Rapivab In-house http://cen.acs.org/articles/87/i39/Flu-Fighters.html Zerbaxa Ceftolozane/tazobactam Cubist Pharmaceuticals small molecules Cephalosporin/beta-lactamase inhibitor Intra-abdominal and urinary tract infections Zerbaxa "Fujisawa Pharmaceutical discovered ceftolozane and licensed it to Calixa Therapeutics, which was acquired by Cubist in 2009" Viekira Pak "Ombitasvir, paritaprevir, and ritonavir tablets copackaged with dasabuvir tablets" AbbVie small molecules "NS5A, NS3/4A, NS5B polymerase inhibitor" Hepatitis C virus Viekira Pak "Paritaprevir was licensed in 2006 from Enanta Pharmaceuticals, ombitasvir was discovered in-house, andritonavir is an antiviral marketed for HIV by AbbVie" Yes "~$83,320 for 12 weeks" Lynparza Olaparib AstraZeneca small molecule PARP inhibitor Ovarian cancer Lynparza "KuDOS Pharmaceuticals, which AstraZeneca acquired in 2005" Yes http://cen.acs.org/articles/91/i24/Pushing-Cancer-Over-Edge.html Xtoro Finafloxacin otic suspension Alcon Laboratories small molecule Topoisomerase and DNA gyrase inhibition Swimmer’s ear Xtoro Licensed from MerLion Pharmaceuticals for otic use in 2011 Blincyto Blinatumomab Amgen bispecific antibody (check) CD19 and CD3 targeted A rare form of acute lymphoblastic leukemia Blincyto "Micromet, which Amgen acquired in 2012" Yes Yes Yes "~$178,000 (two $89,000 cycles)" Esbriet Pirfenidone InterMune/Roche small molecule Unknown Idiopathic pulmonary fibrosis Esbriet "Marnac licensed the rights to pirfenidone in 2007 to InterMune, which was acquired by Roche last year" Yes Yes Yes "~$94,000 per year" http://cen.acs.org/articles/92/i35/Roche-Buy-Intermune.html Ofev Nintedanib Boehringer Ingelheim small molecule "VEGF, FGFR, and PDGFR inhibitor" Idiopathic pulmonary fibrosis Ofev In-house Yes Yes Yes "~$96,000 per year" Lumason Sulfur hexafluoride lipid microsphere Bracco Diagnostics small molecule Contrast imaging agent Certain ultrasound patients Lumason Akynzeo Netupitant/palonosetron Eisai small molecules NK1 substance P receptor antagonist/5-HT3 receptor antagonist [[Yang there are two subscripts in this one]] Nausea in chemotherapy patients Akynzeo "Roche discovered netupitant and licensed it in 2005 to Helsinn, which in 2010 agreed to codevelop the combined product with Eisai" Harvoni Ledipasvir/sofosbuvir Gilead Sciences small molecules NS5A inhibitor/polymerase inhibitor Hepatitis C virus Harvoni "Gilead discovered ledipasvir in-house. Sofosbuvir was discovered by Pharmasset, which was acquired by Gilead in 2011" Yes Yes "~$94,500 for 12 weeks" Trulicity Dulaglutide Eli Lilly & Co. peptide GLP-1 receptor agonist Type 2 diabetes Trulicity In-house Movantik Naloxegol AstraZeneca small molecule Peripherally selective opioid antagonist Opioid-induced constipation Movantik "Nektar Therapeutics, which licensed it in 2009" Keytruda Pembrolizumab Merck & Co. antibody PD-1 inhibitor Melanoma Keytruda "Organon BioSciences, which was acquired by Schering-Plough, which later was acquired by Merck" Yes Yes "~$12,500 per month" Cerdelga Eliglustat Genzyme/Sanofi small molecule Glucosylceramide synthase inhibitor Type 1 Gaucher's disease Cerdelga "Genzyme, which was acquired by Sanofi in 2011" Yes Plegridy Peginterferon beta-1a Biogen Idec glycoprotein Unknown Relapsing multiple sclerosis Plegridy In-house "~$62,035 per year" Belsomra Suvorexant Merck & Co. small molecule Orexin receptor antagonist Insomnia Belsomra In-house Yes http://cen.acs.org/articles/92/i35/FDA-Decision-Loomed-Suvorexant-Chemists.html Orbactiv Oritavancin The Medicines Co. glycopeptide Cell membrane disrupter Skin infections Orbactiv "Discovered by Eli Lilly & Co., sold to InterMune, then to Targanta Therapeutics and acquired by the Medicines Co. in 2009" http://cen.acs.org/articles/86/i15/Uphill-Battle.html Jardiance Empagliflozin Boehringer Ingelheim small molecule SGLT2 inhibitor Type 2 diabetes Jardiance In-house Striverdi Respimat Olodaterol Boehringer Ingelheim small molecule LABA agonist Chronic obstructive pulmonary disease Striverdi Respimat In-house Zydelig Idelalisib Gilead Sciences small molecule PI3K delta inhibitor Three types of blood cancers Zydelig "Calistoga Pharmaceuticals, which Gilead acquired in 2011" Yes Yes "~$7,200 per month" http://cen.acs.org/articles/89/i15/PI3K-Clinical-Crossroads.html Kerydin Tavaborole Anacor Pharmaceuticals small molecule tRNA synthetase inhibition Toenail fungus Kerydin In-house Yes http://cen.acs.org/articles/89/i12/Betting-Boron.html Beleodaq Belinostat Spectrum Pharmaceuticals small molecule pan-HDAC inhibitor Peripheral T-cell lymphoma Beleodaq "TopoTarget, which licensed it to Spectrum in 2010" Yes Sivextro (tablet) Tedizolid Cubist Pharmaceuticals small molecule Bacterial protein synthesis inhibitor Skin infections Sivextro (tablet) "Dong-A Pharmaceutical, which licensed it to Trius Therapeutics. Trius was acquired by Cubist in 2013" http://cen.acs.org/articles/92/i24/Bacterial-Battle.html Jublia Efinaconazole Valeant Pharmaceuticals small molecule 14α-Demethylase inhibitor Toenail fungus Jublia "Kaken Pharmaceutical, which licensed it to Dow Pharmaceutical Sciences. Dow was acquired by Valeant in 2008" Dalvance Dalbavancin Durata Therapeutics glycopeptide Cell wall synthesis inhibition Skin infections Dalvance "Marion Merrell Dow, which sold it to Vicuron Pharmaceuticals. Vicuron was later bought by Pfizer, which sold it to Durata, which was later acquired by Actavis" http://cen.acs.org/articles/92/i24/Bacterial-Battle.html Entyvio Vedolizumab Takeda small molecule Integrin receptor antagonist Ulcerative colitis and Crohn‘s disease Entyvio "Millennium Pharmaceuticals, which was acquired by Takeda in 2008" Zontivity Vorapaxar Merck & Co. small molecule PAR-1 antagonist To reduce the risk of heart attacks and stroke Zontivity "Schering-Plough, which was acquired by Merck in 2009" Yes http://cen.acs.org/articles/89/i16/-Revisiting-Disclosures-Years-Past.html Zykadia Ceritinib Novartis small molecule ALK inhibitor Late-stage non-small-cell lung cancer Zykadia In-house Yes Yes "~$13,500 per month " http://cen.acs.org/articles/91/web/2013/06/Novartis-First-Generation-Lung-Cancer.html Sylvant Siltuximab Johnson & Johnson antibody IL-6 inhibitor Multicentric Castleman’s disease Sylvant In-house Yes Yes Cyramza Ramucirumab Eli Lilly & Co. antibody VEGFR2 inhibitor Advanced stomach cancer Cyramza "ImClone Systems, which was acquired by Lilly in 2008" Yes Tanzeum Albiglutide GlaxoSmithKline peptide GLP-1 receptor agonist Type 2 diabetes Tanzeum "Human Genome Sciences, which was acquired by GSK in 2012" Otezla Apremilast Celgene small molecule PDE4 inhibitor Psoriatic arthritis Otezla In-house Yes Impavido Miltefosine Paladin Labs phospholipid Unknown Leishmaniasis Impavido Licensed from Aeterna Zentaris in 2009 Yes Yes Neuraceq Florbetaben F18 injection Piramal Imaging small molecule Radioactive diagnostic PET imaging of the brain Neuraceq Myalept Metreleptin for injection AstraZeneca peptide Leptin receptor activation Complications of leptin deficiency Myalept "Amylin, which was acquired by Bristol-Myers Squibb in 2012. BMS later partnered diabetes assets with AstraZeneca. Last year, AstraZeneca bought out BMS to fully own Amylin" Yes Yes "~$1,500 per vial (>$150,000 per year for men and >$300,000 per year for women)" Northera Droxidopa Chelsea Therapeutics small molecule Prodrug of norepinephrine and epinephrine Neurogenic orthostatic hypotension Northera Licensed from Dainippon Sumitomo Pharma in 2006 Yes Yes Vimizim Elosulfase alfa BioMarin Pharmaceutical enzyme Enzyme replacement therapy Mucopolysaccharidosis type IVA Vimizim In-house Yes Yes "~$380,000 per year" Hetlioz Tasimelteon Vanda Pharmaceuticals small molecule Melatonin receptor agonist Sleep-wake disorder in the blind Hetlioz "BMS, which licensed it to Vanda in 2004" Yes Farxiga Dapagliflozin Bristol-Myers Squibb/AstraZeneca small molecule SGLT2 inhibitor Type 2 diabetes Farxiga BMS
Originator:Schering-Plough, which was acquired by Merck in 2009. Read More:Volume 89 Issue 16 | p. 38 April 18, 2011 Where Are They Now? Revisiting Disclosures From Years Past
Xtoro
Originator:In-house. Read More:Volume 89 Issue 12 | pp. 18-19 March 21, 2011 Betting On Boron
Zontivity
Kerydin
Originator:Micromet, which Amgen acquired in 2012. Cost:~$178,000 (two $89,000 cycles)
Blincyto
Originator:In-house. Cost:~$13,500 per month Read More:Latest News June 20, 2013 Novartis First-Generation Lung Cancer Drug Tweaked To Reduce Potential Side Effects
Zykadia
Originator:TopoTarget, which licensed it to Spectrum in 2010.
Originator:Marnac licensed the rights to pirfenidone in 2007 to InterMune, which was acquired by Roche last year. Cost:~$94,000 per year Read More:Volume 92 Issue 35 | p. 10 September 1, 2014 Roche To Buy Intermune
Beleodaq
Esbriet
Sylvant
Originator:Dong-A Pharmaceutical, which licensed it to Trius Therapeutics. Trius was acquired by Cubist in 2013. Read More:Volume 92 Issue 24 | pp. 9-14 June 16, 2014 A Bacterial Battle
Sivextro (tablet)
Originator:In-house. Cost:~$96,000 per year
Ofev
Originator:ImClone Systems, which was acquired by Lilly in 2008.
Originator:Roche discovered netupitant and licensed it in 2005 to Helsinn, which in 2010 agreed to codevelop the combined product with Eisai.
Glycopeptide
Cyramza
Akynzeo
Originator:Gilead discovered ledipasvir in-house. Sofosbuvir was discovered by Pharmasset, which was acquired by Gilead in 2011. Cost:~$94,500 for 12 weeks
Originator:Human Genome Sciences, which was acquired by GSK in 2012.
Tanzeum
Harvoni
Opdivo
Originator:Ono Pharmaceutical and Medarex. Medarex was acquired by Bristol-Myers Squibb in 2009. Cost:~$12,500 per month
Otezla
Originator:Licensed from Aeterna Zentaris in 2009.
Rapivab
Impavido
Trulicity
Originator:In-house. Read More:Volume 87 Issue 39 | pp. 15-26 September 28, 2009 Flu Fighters
Orphan drug